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Abstract
Background: SOX genes play an important role in a number of developmental processes. Potential roles of SOXs
have been demonstrated in various neoplastic tissues as tumor suppressors or promoters depending on tumor
status and types. The aim of this study was to investigate the involvement of SOXs in the progression and
prognosis of human prostate cancer (PCa).
Methods: The gene expression changes of SOXs in human PCa tissues compared with non-cancerous prostate
tissues was detected using gene expression microarray, and confirmed by real-time quantitative reverse
transcriptase-polymerase chain reaction (QRT-PCR) analysis and immunohositochemistry. The roles of these genes in
castration resistance were investigated in LNCaP xenograft model of PCa.
Results: The microarray analysis identified three genes (SOX7, SOX9 and SOX10) of SOX family that were
significantly dis-regulated in common among four PCa specimens. Consistent with the results of the microarray,
differential mRNA and protein levels of three selected genes were found in PCa tissues by QRT-PCR analysis and
immunohistochemistry. Additionally, we found that the immunohistochemical staining scores of SOX7 in PCa
tissues with higher serum PSA level (P=0.02) and metastasis (P=0.03) were significantly lower than those with
lower serum PSA level and without metastasis; the increased SOX9 protein expression was frequently found in PCa
tissues with higher Gleason score (P=0.02) and higher clinical stage (P<0.0001); the down-regulation of SOX10
tend to be found in PCa tissues with higher serum PSA levels (P=0.03) and advanced pathological stage (P=0.01).
Moreover, both univariate and multivariate analyses showed that the down-regulation of SOX7 and the up-
regulation of SOX9 were independent predictors of shorter biochemical recurrence-free survival. Furthermore, we
discovered that SOX7 was significantly down-regulated and SOX9 was significantly up-regulated during the
progression to castration resistance.
Conclusions: Our data offer the convince evidence that the dis-regulation of SOX7, SOX9 and SOX10 may be
associated with the aggressive progression of PCa. SOX7 and SOX9 may be potential markers for prognosis in PCa
patients. Interestingly, the down-regulation of SOX7 and the up-regulation of SOX9 may be important mechanisms
for castration-resistant progression of PCa.
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Prostate cancer (PCa) is one of the most prevalent ma-
lignancies in men and the second most frequent cause
of male cancer-related death [1]. It is a clinically
heterogeneous-multifocal disease and the incidence is
continuously rising. Carcinogenesis and the mechanisms
influencing the progression and prognosis of PCa is a
multistep process, involving both genetic insults to epi-
thelial cells and changes in epithelial-stromal interac-
tions. In spite of current therapeutic methods, many
patients develop metastases. Androgen suppression ther-
apies (ASTs) have already been considered as the main-
stay of systemic treatment for advanced PCa, especially
for metastatic disease [2]. Most patients respond to AST
and their clinical symptoms could be relieved, although
they eventually experience disease relapse and develop
more aggressive tumors, commonly termed 'hormone-
refractory prostate cancer' or 'castration-resistant pros-
tate cancer' [3]. The clinical benefits of AST for various
PCa patients are different. Even among patients with
metastatic PCa, for which AST is the established stand-
ard of care, the length of clinical remission induced by
AST can range from months to more than 10 years [4].
Although some clinical parameters, such as serum pros-
tate specific antigen (PSA) levels, may provide some
prognostic utility in the treatment settings, there are
currently no definitive clinical methods that can reliably
predict the responses to clinical therapies for PCa. Thus,
it is of great significance to search for a more sensitive
and more specific PCa marker that can provide valuable
information for the diagnosis and treatment of the
disease.
SOX genes belong to the High Mobility Group (HMG)
superfamily and encode transcription factors which can
be identified based on a conserved motif within the
HMG domain, RPMNAFMVW [5]. It has been demon-
strated that the SOX genes can regulate a number of de-
velopmental processes, including lens, hair follicle, gut,
B-cell, muscle, and blood vessel development [6]. Their
potential roles have also been found in various neoplas-
tic tissues as tumor suppressors or promoters depending
on tumor status and types. Of our interests, Wang et al.
[7,8] found that SOX9 is expressed in primary PCa
in vivo, at a higher frequency in recurrent PCa and in
PCa cell lines. They also demonstrated that the suppres-
sion of SOX9 by siRNA in PCa cells may reduce en-
dogenous androgen receptor (AR) protein levels and cell
growth, which suggested that SOX9 may contribute to
androgen receptor regulation and decreased cellular pro-
liferation of PCa. In addition, Katoh et al. [9,10] detected
the SOX7 expression in various normal and tumor tis-
sues. They found that SOX7 mRNA was relatively highly
expressed in a gastric cancer and esophageal cancer cell
lines, but was significantly down-regulated in primary
colorectal tumor, breast cancer, kidney tumor, lung can-
cer and PCa tissues.
Perplexing expression patterns of SOXs in PCa have
not been clear. To address this problem, in our studies,
SOX7, SOX9 and SOX10 were identified as target genes
because of their statistically differential expression in
PCa tissues detected by the gene microarray. In addition,
expression states of the mRNA and protein of these can-
didate genes were evaluated further by real-time quanti-
tative reverse transcriptase-polymerase chain reaction
(QRT-PCR) analysis, and semi-quantitative immunohis-
tochemistry in a large series of PCa and adjacent benign
prostate tissues. Then, the clinicopathological relevance
and prognostic value of SOX7, SOX9 and SOX10 pro-
teins have also been determined. Furthermore, the roles
of SOX7, SOX9 and SOX10 genes in castration resist-
ance were investigated in a LNCaP xenograft model of
PCa.
Methods
Patients and tissue samples
The study was approved by the Research Ethics Com-
mittee of Guangzhou First Municipal People’s Hospital,
Affiliated Guangzhou Medical College, China. Informed
consent was obtained from all of the patients. All speci-
mens were handled and made anonymous according to
the ethical and legal standards.
For gene microarray analysis, 4 pairs of prostate pri-
mary tumor and benign tissues adjacent to tumor were
collected from the tissue bank at Guangzhou Medical
College. The detail information on these tissues has been
described in our previous study [11].
For QRT-PCR analysis, 10 fresh PCa tissues (aging
54~87 years, mean±SD=73.9±10.9 years, TNM sta-
ging from I to III) and paired 10 adjacent benign tissues
of prostate were provided by the Guangzhou First Muni-
cipal People’s Hospital. Among them, 4 pairs of samples
are the same with gene microarray analysis.
For semiquantitative immunohistochemistry, tissue
microarray was provided by the Massachusetts General
Hospital. There include 147 PCa tissues (aging
37~83 years, mean±SD=58.2±7.0 years, TNM staging
from I to III) and 28 paired adjacent benign tissues.
All of the tissues were obtained immediately during
the operation of transurethral resection prostate and
suprapubic prostatectomy. None of the patients
recruited in this study had chemotherapy or radiother-
apy before the surgery. The pathological diagnosis was
performed preoperatively and confirmed postoperatively.
All patients were reviewed and all specimens were re-
examined in March, 2010. TMN grade and Gleason
Score were examined by the same group of two senior
pathologists experienced in PCa diagnosis. The detail
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study was shown in Table 1.
The patients involved in the semiquantitative immu-
nohistochemistry were given a follow-up exam ranging
from 3 to 12 years. For the analysis of survival and
follow-up, the date of prostatectomy was used to repre-
sent the beginning of the follow-up period. The primary
analysis endpoint was biochemical recurrence-free sur-
vival. Others analysis endpoints were overall survival
and metastasis-free survival. All the patients who died
from diseases other than PCa or from unexpected events
were excluded from the case collection.
Animals and xenograft tumor establishment
All experiments involving laboratory animals were done
in accordance with the Guideline for Animal Experi-
ments of Guangzhou Medical College and approved by
Animal Research Committee at Guangzhou Medical
College. 6–8 weeks old male athymic mice (BALB/c
strain, Charles River Laboratory, Montreal, PQ, Canada)
were used.
Early passage LNCaP cells were grown in RPMI 1640
(Life Technologies) with 10% fetal bovine serum (FBS),
100 units/mL penicillin, and 100 μg/mL streptomycin
under 5% CO2. Cells underwent 4-8 passages prior to
mouse inoculation. Approximately 10
6 LNCaP cells sus-
pended in 250 μl media were mixed with 250 μl Matrigel
(Becton Dickinson labware, Bedford, MA) and then
inoculated subcutaneously in the flank region of athymic
mice using a 25-gauge needle.
Treatment protocol and tissue sampling
Once established at 8-12 weeks after injection, tumors
were measured biweekly. Tumor volumes were mea-
sured with a caliper using the formula: length×width
2×
0.52. The mice bearing xenograft tumors were castrated
after the xenograft volume reached 150 mm
3. The se-
quential changes in tumor volume were analyzed. Serum
samples were obtained at sacrifice to measure PSA
values using a sandwich enzyme immunoassay kit
(CAN-tPSA-4300, Diagnostics Biochem Canada Inc.,
Ontario, Canada) with a lower limit of detection of
0.1 ng/ml. Xenograft tissues of mice were collected dur-
ing various stages and total RNA was isolated and puri-
fied using the RNeasy Mini Kit (Qiagen).
Gene microarray analysis
The gene microarray analysis has been reported by our
previous study [11] and the microarray raw data have
been depostied at GEO under the accession number
GSE28204.
Real-time quantitative reverse transcriptase PCR
Quantitative PCR was used to examine the expression
status of the three candidate genes which have statisti-
cally differential expression in PCa tissues compared
with non-cancerous prostate tissues detected by gene
microarray analysis.
The cDNA templates for qRT-PCR were synthesized
from RNA samples. The primers 5'- TGA GCC AGG
TGG AAC TCC T -3' and 5'- CTG GGA GAC CGG AAC
ATG C -3' were used to amplify 125-bp transcripts of
SOX7, the primers 5'- AGC GAA CGC ACA TCA AGA
C -3' and 5'- GCT GTA GTG TGG GAG GTT GAA -3'
were used to amplify 110-bp transcripts of SOX9, the pri-
mers 5'- CCC ACA CTA CAC CGA CCA G -3' and 5'-
GGC CAT AAT AGG GTC CTG AGG -3' were used to
amplify 143-bp transcripts of SOX10, and the primers 5'-
GGT GGC TTT TAG GAT GGC AAG -3' and 5'- ACT
GGA ACG GTG AAG GTG ACA G -3' were used to
amplify 161-bp transcripts of β-actin. Gene expression
was determined using SYBR Green PCR mix (Toyoko)
and 1 μg of template. Real-time PCR was performed on a
MyiQ.2 Two-Color Real-Time PCR Detection System
(Bio-Rad), using the following amplification conditions:
5 min, 95°C; followed by 40 cycles of 10 seconds 95°C, 20
seconds 60°C and 20 seconds 72°C. All assays were carried
out in triplicate. CT-values were determined using the
IQ5 software (Bio-Rad). Gene expression in each sample
was normalized with the housekeeping gene (β-actin) ex-
pression. Relative quantification of target gene expression
was evaluated using the comparative cycle threshold
(CT) method.
Table 1 Clinical features of all patients
Sample type &
Clinical features
Experiment type (cases)
Microarray RT-QPCR IHC
Prostate cancer 4 10 147
Mean age (range, years) 70.25±11.6154 73.90±10.8572 58.17±7.038
(54-80) (54-87) (37-83)
≤6 0 129 9
>6 0 384 8
Serum PSA levels (ng/ml)
<1 0 111 0
≥1 0 397 4
Gleason score
<8 242 9
≥8 2 6 118
Metstasis 0 0 19
Adjacent benign prostate
tissue
41 0 2 8
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The specimens were fixed in 10% neutral buffered for-
malin and subsequently embedded in paraffin. The
paraffin-embedded tissues were cut at 3 μm and then
deparaffinized with xylene and rehydrated for further
H&E or peroxidase (DAB) immunohistochemistry stain-
ing employing DAKO EnVision System (Dako Diagnos-
tics, Zug, Switzerland). Briefly, following a brief
proteolytic digestion and a peroxidase blocking of tissue
slides, the slides were incubated overnight with the pri-
mary antibodies against respective target proteins (SOX7
Ab., Santa Cruz #sc-20093; SOX9 Ab., Santa Cruz #sc-
20093; SOX10 Ab., Santa Cruz # sc-17342) at a dilution
of 1:50 (SOX7 and SOX10) and 1:100(SOX9) at 4°C.
After washing, peroxidase labeled polymer and
substrate-chromogen were then employed in order to
visualize the staining of the interested proteins. In each
immunohistochemistry run, negative controls were car-
ried out by omitting the primary antibody, whereas the
overexpressions of respective target proteins confirmed
by western blotting was used as positive controls.
Following a hematoxylin counterstaining, immunos-
taining was scored by two independent experienced
pathologists, who were blinded to the clinicopathological
data and clinical outcomes of the patients. The scores of
the two pathologists were compared and any discrepant
scores were trained through re-examining the stainings
by both pathologists to achieve a consensus score. The
number of positive-staining cells in ten representative
microscopic fields was counted and the percentage of
positive cells was calculated. Given the homogenicity of
the staining of the target proteins, tumor specimens were
scored in a semi-quantitative manner. The percentage
scoring of immunoreactive tumor cells was as follows: 0
(0%), 1 (1-10%), 2 (11-50%) and 3 (>50%). The staining in-
tensity was visually scored and stratified as follows: 0
(negative), 1 (weak), 2 (moderate) and 3 (strong). A final
immunoreactivity scores (IRS) was obtained for each case
by multiplying the percentage and the intensity score. Pro-
tein expression levels were further analyzed by classifying
IRS values as low (based on a IRS value less than 4) and as
high (based on a IRS value greater than 4).
Western blot analysis
For western blot analysis, 40 μg of whole cell extracts
were fractioned by SDS-PAGE and transferred onto
Hybond nitrocellulose membranes (GE Healthcare). Fil-
ters were blocked in PBS-Tween 20/5% skim milk and
probed with antibodies against respective target proteins
(SOX7 Ab., Santa Cruz #sc-20093; SOX9 Ab., Santa
Cruz #sc-20093; SOX10 Ab., Santa Cruz # sc-17342) at a
dilution of 1:50 (SOX7 and SOX10) and 1:100 (SOX9),
or probed with anti-β-catenin antibodies, which were
visualized by SuperSignal West PICO chemiluminescent
detection system (Pierce Biotechnology). β-actin was
used as equal protein loading control.
Statistical analysis
The software of SPSS version13.0 for Windows (SPSS
Inc, IL, USA) and SAS 9.1 (SAS Institute, Cary, NC) was
used for statistical analysis. Continuous variables were
expressed as X
  s. Statistical analysis were performed
with Fisher's exact test for any 2×2 tables, Pearson χ
2
test for non-2×2 tables, Kaplan-Meier method for the
question of survival, Chiquest trend test for ordinal data,
and Cox regression analysis for the multivariate analysis.
The Spearman correlation was calculated between the
expression levels of SOX7, SOX9 and SOX10 in PCa tis-
sues. Differences were considered statistically significant
when p was less than 0.05.
Results
Identification of candidate target SOX genes for PCa by
gene microarray analysis
In the search for SOX genes involved in the development
of human PCa, we compared gene expresion between 4
pairs of PCa and adjacent benign prostate tissue samples.
As the results, three SOX genes--SOX7 (p<0.001) and
SOX10 (p=0.010) were down-regulated, but SOX9
(p=0.029) was up-regulated in all PCa tissue samples
(Table 2).
Validation of the gene microarray results by real-time
quantitative RT-PCR
To further validate the results of gene microarray ana-
lysis, we performed QRT-PCR to detect the mRNA ex-
pression levels of SOX7, SOX9 and SOX10 in 10 PCa
and 10 adjacent benign prostate tissues. We found that
SOX7 (p<0.01) and SOX10 (p<0.01) genes showed a
significant down-regulation in tumor tissues and SOX9
(p<0.01) gene showed a significant up-regulation in
tumor tissues when compared to corresponding adjacent
benign prostate tissues, although the fold change in the
expression level was not exactly same between the
microarray analysis and QRT-PCR (Figure 1).
Expression of SOX7, SOX9 and SOX10 proteins in PCa
and adjacent benign prostate tissues
The expression and localization of SOX7, SOX9 and
SOX10 in the 147 PCa and 28 adjacent benign prostate tis-
sues were examined using immunohistochemical analysis.
The expression levels of SOX7 (IRS: PCa=4.01±0.160 vs.
Benign=4.79±0.279, p=0.024) and SOX10 (IRS: PCa=
2.76±0.174 vs. Benign=4.00±0.424, p=0.010) in PCa tis-
sues were lower than those in adjacent benign prostate tis-
sues significantly (Figure 2). But the expression level of
SOX9 in PCa tissues were higher than that in adjacent
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nign=5.96±0.461, p=0.041) significantly (Figure 2). The
SOX7 and SOX9 expression occurred mainly in the nu-
cleus, while SOX10 in the cytoplasm, which is similar to
the results from the previous studies [10,12]. Representa-
tive pictures of immunohistochemistry staining of SOX7,
SOX9 and SOX10 are shown in Figure 3. In addition, the
Spearman Correlation analysis showed that the expression
level of SOX7 protein in PCa tissues was significantly
negative correlated with that of SOX9 protein (rs=-0.408,
p<0.001) and positive correlated with that of SOX10 pro-
tein (rs=0.513, p<0.001), respectively; the expression
level of SOX9 protein was also significantly negative corre-
lated with that of SOX10 protein (rs=-0.219, p=0.008).
Association of SOX7, SOX9 and SOX10 expression with
the clinicopathological characteristics of PCa
The association of SOX7, SOX9 and SOX10 expression
with the clinicopathological features of PCa patients is
shown in Table 3. The immunohistochemical staining
scores of SOX7 in PCa tissues with higher serum PSA
level (P=0.021) and metastasis (P=0.025) were signifi-
cantly lower than those with lower serum PSA level and
without metastasis; the increased SOX9 protein expres-
sion was frequently found in PCa tissues with higher
Gleason score (P=0.024) and higher clinical stage
(P<0.0001); the down-regulation of SOX10 tend to be
found in PCa tissues with higher serum PSA levels
(P=0.025) and advanced pathological stage (P=0.013).
Prognostic implications of SOX7, SOX9 and SOX10
expression in PCa
The association of the expression levels of SOX7, SOX9
and SOX10 with the biochemical recurrence-free survival,
overall survival and metastasis-free survival of PCa patients
was analyzed using Kaplan-Meier method (Figure 4). The
data indicated that there were no significant differences in
overall and metastasis-free survival between high expres-
sion group and low expression group of SOX7 and SOX10
(all p>0.05). Interestingly, the results by pairwise compari-
sons showed that there is a significant difference in the bio-
chemical recurrence-free survival rates between patients
with high SOX7 expression and low SOX7 expression
Table 2 Microarray data of SOX family genes
Gene Symbol Gene_ID regulation Fold_change p-value
SOX1 6656 up 1.19 0.358
SOX2 6657 down 4.37 0.146
SOX3 6658 down 1.29 0.353
SOX4 6659 up 1.77 0.435
SOX5 6660 down 2.11 0.137
SOX6 55553 down 1.23 0.358
SOX7 83595 down 2.11 <0.001
SOX8 30812 up 1.44 0.404
SOX9 6662 up 1.57 0.029
SOX10 6663 down 1.69 0.010
SOX11 6664 up 1.82 0.226
SOX12 6666 up 1.99 0.399
SOX13 9580 down 1.25 0.461
SOX14 8403 up 1.03 0.055
SOX15 6665 up 1.42 0.271
SOX17 64321 up 1.35 0.161
SOX18 54345 up 1.22 0.407
SOX21 11166 up 1.62 0.053
SOX2OT 347689 down 1.59 0.248
SOX30 11063 up 1.21 0.504
Note: Genes marked with grey color were significantly differentially expressed
in PCa tissues compared with non-cancerous prostate tissues.
Figure 1 Validation of gene microarray data by real-time
quantitative RT-PCR (qRT-PCR). Three genes were subjected to
QRT-PCR in the mRNA from ten pairs of PCa and adjacent benign
prostate tissues. The significant down-regulation of SOX7 and SOX10
and up-regulation of SOX9 were detected in PCa tissues (n=10)
than that in the corresponding adjacent benign prostate tissues (all
P<0.01). Relative expression ratio is defined as the expression levels
of the gene to those of the internal reference gene, β-actin. The
assays were carried out in triplicate and means±standard deviations
were plotted.
Figure 2 Immunoreactivity scores (IRS) of SOX7, SOX9 and
SOX10 in PCa and Benign tissues.
*p<0.05 and
**p<0.001 in
comparison between the IRS of three proteins in PCa and Benign
tissues.
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survival and overall survival rates of patients with high
SOX9 expression were significantly lower than those with
low SOX9 expression (p=0.017 and 0.046), respectively.
Furthermore, the multivariate analyses showed that the
down-regulation of SOX7 (P=0.010) and the up-regulation
of SOX9 (P=0.008) were independent predictors of shorter
biochemical recurrence free-survival (Table 4).
Changes of SOX7, SOX9 and SOX10 expression in the
progression of castration resistance in PCa
Nine xenograft tumor mouse models were established in
this study and the xenograft tumor tissues were collected
during androgen-dependent growth (AD), castration-
induced regression nadir (ND), and castration-resistant re-
growth (CR) stages (n=3 for each stage). The tumor
volumes were 3,620±318 mm
3, 697±182 mm
3,a n d
2,288±301 mm
3, and the median PSA values of the mice
were 189.2 ng/mL, 4.3 ng/mL and 68.7 ng/mL for the AD,
ND, and CR stages, respectively.
\Nextly, we evaluated the gene expression levels of SOX7,
SOX9 and SOX10 at each stage using real-time quantitative
RT-PCR. We found that the relative expression ratios of
SOX7 mRNA to β-actin mRNA were 0.39, 0.82 and 0.51,
t h er e l a t i v ee x p r e s s i o nr a t i o so fS O X 9m R N At oβ-actin
mRNA were 1.68, 0.56 and 1.13, and the relative expression
Figure 3 Immunohistochemical staining for SOX7, SOX9 and SOX10 in PCa (Original magnification×200). a, SOX7 strongly positive
staining was found in cytoplasm of Benign tissue; b, SOX7 weakly positive staining in PCa was found in cytoplasm of PCa tissues; c, SOX9 weakly
positive staining was found in nucleus of Benign tissue; d, SOX9 strongly positive staining in PCa was found in nucleus of PCa tissues; e, SOX10
strongly positive staining was found in cytoplasm of Benign tissue; f, SOX10 weakly positive staining in PCa was found in cytoplasm of PCa
tissues.
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and 0.61 for the AD, ND, and CR stages, respectively
(Figure 5). The changes of SOX7 and SOX9 expression in
different stages had statistically significance, but that of
SOX10 had not. These results indicated that SOX7 gene
expression levels were significantly increased from the AD
stage to the ND stage (AD vs. ND: P=0.009), but decreased
at the CR stage (P=0.02). To be opposite, SOX9 gene ex-
pression levels were significantly decreased from the AD
stage to the ND stage (AD vs. ND: P=0.007), and also
recovered at the CR stage (ND vs. CR: P=0.01).Consistent
with the trends at gene levels, the expression levels of
SOX7 protein detected by Western blot analysis were sig-
nificantly increased from the AD stage to the ND stage
(AD vs. ND: P=0.01, Figure 6), but decreased at the CR
stage (P=0.02, Figure 6). In contrast, the expression levels
of SOX9 protein were significantly reduced from the AD
stage to the ND stage (AD vs. ND: P=0.006, Figure 6), and
also recovered at the CR stage (ND vs. CR: P=0.01,
Figure 6).
Discussion
PCa is the most frequently occurring cancer in men and
advanced metastatic PCa is currently incurable. It is the
great challenge of current basic and clinical research to
identify novel molecular markers that could improve the
tumor classification and prognostic stratification of PCa.
The main findings of the present study are as following five
points. Firstly, using gene microarray system, SOX7, SOX9
and SOX10 were identified as candidate genes which were
differentially expressed in PCa compared with non-
cancerous prostate tissues; Secondly, the de-regulation of
SOX7, SOX9 and SOX10 genes and proteins in PCa tissues
were further confirmed by real-time quantitative RT-PCR
and immunohistochemistry analysis; Thirdly, the expression
levels of SOX7, SOX9 and SOX10 in PCa tissues were
related to the severity of the tumor malignancy; Fourthly,
the down-regulation of SOX7 and the up-regulation of
SOX9 were both independent predictors of shorter bio-
chemical recurrence free-survival of patients with PCa; and
finally, the down-regulation of SOX7 and the up-regulation
of SOX9 at both gene and protein levels were observed dur-
ing castration-resistant progression in xenograft tumor
mouse models. These results suggest the SOX7, SOX9 and
SOX10 play important roles in the pathogenesis and
aggressiveness of PCa, and SOX7 and SOX9 especially be
associated with the prognosis and be involved in the
castration-resistant progression of PCa.
The main functions of the SOX gene family are as fol-
lowing [13-16]: Firstly, SOX genes regulate specification
and differentiation of many cell types, such as neurogen-
esis, neural crest development, chondrogenesis, male sex
gonad or respiratory epithelium development, melano-
cyte differentiation, and the differentiation of Paneth
cells in the gut; Secondly, SOX genes within the same
subgroup often share functional roles; Thirdly, SOX
genes within the same subgroup can counteract the
function of genes in another subgroup, and fourthly the
same SOX gene can mediate different stages of develop-
ment in one cell type and/or developmental processes in
more than one cell type. Based on phylogenetic analysis
of their HMG domains, SOX genes can be separated
into subgroups A-J, A-H of which are represented in
mouse and humans [17]. Because they are expressed in
many tissues, it is not surprisingly that SOX genes are
implicated in the etiology of many diseases and certain
cancers. In the present study, we identified three SOX
genes (SOX7, SOX9 and SOX10) as the genes of inter-
est, because they were differentially expressed in PCa
compared with adjacent benign prostate tissues using
the gene microarray system (Table 2). The down-
regulation of SOX7 and SOX10, and the up-regulation
SOX9 genes and proteins in PCa tissues were further
confirmed by the real time quantitative RT-PCR and
immunohistochemistry analysis, when compared to the
corresponding non-cancerous prostate tissues.
SOX7 gene belongs to SOX subgroup F, which also
includes SOX17 and SOX18 [18]. It encodes a
Table 3 Relationship between immunoreactivity scores of
SOX7, SOX9, SOX10 and clinicopathological features of
PCa
Clinical
features
(Numbers)
SOX7 SOX9 SOX10
IRS P IRS P IRS P
X̅ ±sX ̅ ±sX ̅ ± s
Age (years)
< 70 (75) 3.93±0.219 0.530 7.46± 0.268 0.114 2.73±0.215 0.875
≥70 (72) 4.14±0.224 6.68± 0.403 2.79±0.295
Serum PSA Levels (ng/ml)
<4 (27) 4.50±0.330 0.021 7.17± 0.560 0.968 3.29±0.456 0.025
≥4 (120) 3.34±0.183 7.14± 0.251 2.33±0.185
Gleason Score
< 8 (118) 4.09±0.183 0.317 5.93± 0.606 0.024 2.66±0.188 0.276
≥8 (29) 3.69±0.322 7.46± 0.235 3.14±0.438
Clinical Stage
<T2A(79) 3.95±0.205 0.431 6.39± 0.326 <0.001 2.62±0.226 0.498
≥T2A(68) 4.21±0.259 8.25± 0.270 2.86±0.269
Pathological Stage
T2A-T2C(86) 4.06±0.209 0.742 7.23± 0.282 0.693 3.53±0.214 0.013
T3A-T4(61) 3.95±0.249 7.05± 0.381 2.27±0.287
Metstasis
No (119) 4.88±0.179 0.025 7.34± 0.240 0.104 2.67±0.186 0.327
Yes (28) 3.75±0.359 6.39± 0.611 3.11±0.455
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http://www.biomedcentral.com/1471-2407/12/248transcription factor that can both enhance and inhibit
transcription. SOX7 is mainly implicated in parietal
endoderm differentiation [19]. According to the previous
studies, SOX7 mRNA is undetected in some human can-
cer cell lines including HeLa S3 (cervical cancer), K562
(chronic myelogenous leukemia), SW480 (colorectal
cancer), etc., suggesting that SOX7 might be a tumor
suppressor gene in these cancers [20]. In PCa, SOX7
mRNA and protein expressions were both shown to be
down-regulated, which was consistent with the findings
of this study and was found to be due to tumor-specific
promoter hypermethylation present in PCa tissues and
PCa cell lines/xenografts [10]. Interestingly, we further
demonstrated that the expression level of SOX7 protein
in PCa tissues with higher serum PSA level and metasta-
sis were significantly lower than those with lower serum
PSA level and without metastasis. SOX9, together with
Figure 4 Kaplan-Meier survival curves of the biochemical recurrence-free survival, overall survival and metastasis-free survival for
SOX7 (a, b and c, respectively), SOX9 (d, e and f, respectively) and SOX10 (g, h and i, respectively) expression in PCa.
Table 4 Prognostic value of SOX7 and SOX9 expression
for the biochemical recurrence-free survival in
multivariate analysis by Cox Regression
Hazard ratio (95% CI) P value
SOX7 expression 0.81 (0.14-4.55) 0.010
SOX9 expression 0.20 (0.06-0.66) 0.008
Gleason Score 1.57 (0.71-3.45) 0.261
Pathological Stage 1.76 (0.54-5.72) 0.346
Serum PSA Levels 1.05 (0.98-1.12) 0.161
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http://www.biomedcentral.com/1471-2407/12/248SOX8 and SOX10, belongs to SOX subgroup E [21,22].
It is a downstream effector of SRY, which in turn is
dependent on the activity of androgens and the AR.
There have been several studies on the involvement of
SOX9 in PCa. In 2004, Drivdahl et al. [23] found that
the elevated expression of SOX9 in PCa cell lines
resulted in a decreased rate of cellular proliferation, cell
cycle arrest in G0/G1, and increased sensitivity to apop-
tosis. In 2007 and 2008, Wang et al. [7,8] also demon-
strated that SOX9 was expressed in PCa cells and was
increased in relapsed hormonerefractory PCa. In 2010,
Thomsen et al. [12] identified SOX9 as part of a devel-
opmental pathway that is reactivated in prostate neopla-
sia where it promotes tumor cell proliferation. All these
previous studies were similar to the findings of our
study. SOX10 has been implicated in the late stage of
neural crest cell formation, maintenance of multipotency
crest cells as stem cells and specification of derivative
cell fates to Schwannian and melanocytic destinations
[24-26]. Mutations in the SOX10 gene have been
reported in a fraction of both primary and metastatic
melanoma tumors [27]. The immunohistochemistry ana-
lysis has also been employed to map the expression of
SOX10 in various human tissues and SOX10 has been
suggested to be a specific and sensitive marker for mela-
nocytic tumors [28]. However, the role of SOX10 in the
development of PCa is not clear. From our investigation,
SOX10 has been shown to be down-regulated and was
associated with the high serum PSA levels and advanced
pathological stage in PCa tissues.
An accurate prediction of the probability of disease
recurrence is essential for proper therapy selection of
PCa tissues. Thus, we investigated the prognostic sig-
nificances of SOX7, SOX9 and SOX10 in the present
study. Our results revealed that the expression of
SOX7 and SOX9 in PCa correlated with biochemical
recurrence-free survival. Patients with shorter follow-up
time had tumors with a significantly lower expression
of SOX7 and higher expression of SOX9, which indi-
cated that tumors in patients with biochemical recur-
rence harbored SOX7 down-regulation and SOX9 up-
regulation. In order to determine whether three SOX
genes are involved in the progression to castration re-
sistance PCa, we detected the changes of their expres-
sion in xenograft tumor mouse models. Our data
showed the SOX7 down-regulation and the SOX9 up-
regulation during the process of castration resistance,
which suggested that the de-regulation of SOX7 and
SOX9 may be one of the mechanisms responsible for
the progression to castration resistance PCa. The exact
roles of SOX7, SOX9 and SOX10 in the development
of castration resistance are worth to be further
investigation.
Conclusions
In conclusion, our data offer the convince evidence that
the de-regulation of SOX7, SOX9 and SOX10 may be
associated with the aggressive progression of PCa. SOX7
Figure 5 Changes of SOX7, SOX9 and SOX10 mRNA expression
levels in the progression of castration resistance in PCa. (a)
SOX7, SOX9 and SOX10 mRNA expression levels during
androgen-dependent growth (AD), castration-induced regression
nadir (ND), and castration-resistant regrowth (CR) stages detected
by real-time quantitative RT-PCR. (b) The relative expression ratios
of SOX7, SOX9 and SOX10 mRNA to β-actin mRNA during the AD,
ND and CR stages, respectively. ‘*’ P<0.05 compared with ND;
‘**’P<0.01 compared with AD.
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http://www.biomedcentral.com/1471-2407/12/248and SOX9 may be potential markers for prognosis in
PCa patients. Interestingly, the down-regulation of
SOX7 and the up-regulation of SOX9 may be possible
mechanisms for castration-resistant progression of PCa.
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